To read the full story, subscribe or sign in.

Adamas’ MS therapy hits primary endpoint, and yet it …

Dec. 17, 2019

While the market gave Adamas Pharmaceuticals Inc. shares a thrashing Tuesday, newly installed CEO Neil McFarlane wouldn’t call it quits on the data generated from the phase III of ADS-5102, the Inroads study for treating multiple sclerosis patients with walking impairment.

BioWorld Clinical Immune

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld Asia

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Data needed for Chinese COVID-19 vaccines against Delta variant

BioWorld

The lack of data surrounding the efficacy of Chinese COVID-19 vaccines against the Delta variant has had many questioning them, especially after a recent study...

Today's news in brief

BioWorld

BioWorld briefs for July 30.

Today's news in brief

BioWorld MedTech

BioWorld MedTech's briefs for July 30.

Aicuris heads for phase III with herpes drug pritelivir

BioWorld

Aicuris Anti-Infective Cures AG is beginning the pivotal phase III part of its trial of pritelivir for herpes simplex virus infection after an encouraging...